Page last updated: 2024-08-22

betamethasone-17,21-dipropionate and pulmicort

betamethasone-17,21-dipropionate has been researched along with pulmicort in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19904 (57.14)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andersson, PH; Brattsand, R; Thalén, A1
Malmsten, LA; Scott, M; Thelin, I1
Lassus, A; Salde, L1
Fredriksson, T; Salde, L1
Fletcher, A; Keegel, T; Milne, R; Nixon, R; Sajjachareonpong, P; Saunders, H1
Calzavara-Pinton, P; Rossi, MT; Sala, R; Venturini, M1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1

Trials

4 trial(s) available for betamethasone-17,21-dipropionate and pulmicort

ArticleYear
Effect on plasma cortisol level and urinary cortisol excretion, in healthy volunteers, after application of three different topical steroid ointments under occlusion.
    Acta dermato-venereologica, 1981, Volume: 61, Issue:6

    Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Budesonide; Glucocorticoids; Humans; Hydrocortisone; Male; Occlusive Dressings; Ointments; Pregnenediones

1981
Systemic side-effects of three topical steroids in diseased skin.
    Current medical research and opinion, 1983, Volume: 8, Issue:7

    Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Betamethasone; Betamethasone Valerate; Budesonide; Clinical Trials as Topic; Dermatitis, Exfoliative; Female; Glucocorticoids; Humans; Male; Middle Aged; Pregnenediones; Psoriasis

1983
A double-blind trial of budesonide and betamethasone- 17,21-dipropionate in psoriasis.
    Current medical research and opinion, 1982, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Aged; Betamethasone; Budesonide; Child; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Occlusive Dressings; Pregnenediones; Psoriasis

1982
The separate daily application of tacalcitol 4 µg/g ointment and budesonide 0.25 mg/g cream is more effective than the single daily application of a two compound ointment containing calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2011, Volume: 146, Issue:4

    Topics: Administration, Cutaneous; Adult; Aged; Betamethasone; Budesonide; Calcitriol; Dermatologic Agents; Dihydroxycholecalciferols; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ointments; Pruritus; Psoriasis; Time Factors; Young Adult

2011

Other Studies

3 other study(ies) available for betamethasone-17,21-dipropionate and pulmicort

ArticleYear
Development of glucocorticosteroids with enhanced ratio between topical and systemic effects.
    Acta dermato-venereologica. Supplementum, 1989, Volume: 151

    Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Betamethasone; Betamethasone Valerate; Biotransformation; Budesonide; Dose-Response Relationship, Drug; Humans; Hydrocortisone; Liver; Male; Mice; Pregnenediones; Rats; Rats, Inbred Strains; Structure-Activity Relationship

1989
Topical corticosteroid allergy in an urban Australian centre.
    Contact dermatitis, 2004, Volume: 50, Issue:1

    Topics: Administration, Topical; Adult; Australia; Betamethasone; Betamethasone Valerate; Budesonide; Dermatitis, Allergic Contact; Dermatitis, Occupational; Drug Utilization; Female; Glucocorticoids; Humans; Hydrocortisone; Male; Middle Aged; Patch Tests; Practice Patterns, Physicians'; Prevalence; Retrospective Studies; Triamcinolone Acetonide

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004